Table 1.
Relationship of FAT2 expression with pathological parameters of GC
| Clinical parameters | FAT2 | |||
|---|---|---|---|---|
|
| ||||
| Low | High | t/χ2 | P | |
| Age (yrs) | 58.24±12.08 | 61.04±12.04 | -2.194 | 0.029 |
| Gender | 1.298 | 0.255 | ||
| Male | 226 (72.7%) | 85 (27.3%) | ||
| Female | 84 (67.2%) | 41 (32.8%) | ||
| Location | 4.703 | 0.095 | ||
| Proximal | 38 (69.1%) | 17 (30.9%) | ||
| Middle | 107 (65.6%) | 56 (34.4%) | ||
| Distal | 165 (75.7%) | 53 (24.3%) | ||
| Size | 14.889 | < 0.01 | ||
| < 5 cm | 200 (78.1%) | 56 (21.9%) | ||
| ≥ 5 cm | 110 (61.1%) | 70 (38.9%) | ||
| Lauren classification | 92.260 | < 0.01 | ||
| Intestinal | 204 (91.5%) | 19 (8.5%) | ||
| Diffuse | 106 (49.8%) | 107 (50.2%) | ||
| Histology classification | 1.115 | 0.773 | ||
| Papillary adenocarcinoma | 11 (68.8%) | 5 (31.2%) | ||
| Tubular adenocarcinoma | 236 (72.4%) | 90 (27.6%) | ||
| Mucinous adenocarcinoma | 19 (65.5%) | 10 (34.5%) | ||
| Signet-ring cell carcinoma | 44 (67.7%) | 21 (32.3%) | ||
| Histologic differentiation | 5.155 | 0.161 | ||
| Well | 12 (92.3%) | 1 (7.7%) | ||
| Moderately | 95 (74.2%) | 33 (25.8%) | ||
| Poorly | 201 (68.6%) | 92 (31.4%) | ||
| Others | 2 (100.0%) | 0 (0.0%) | ||
| Invasion depth | 40.029 | < 0.01 | ||
| T1 | 52 (91.2%) | 5 (8.8%) | ||
| T2 | 93 (85.3%) | 16 (14.7%) | ||
| T3 | 154 (63.1%) | 90 (36.9%) | ||
| T4 | 11 (42.3%) | 15 (57.7%) | ||
| Lymphatic metastasis | 61.263 | < 0.01 | ||
| No | 154 (92.8%) | 12 (7.2%) | ||
| Yes | 156 (57.8%) | 114 (42.2%) | ||
| Regional lymph nodes | 87.333 | < 0.01 | ||
| PN0 | 154 (92.8%) | 12 (7.2%) | ||
| PN1 | 95 (69.9%) | 41 (30.1%) | ||
| PN2 | 51 (51.5%) | 48 (48.5%) | ||
| PN3 | 10 (28.6%) | 25 (71.4%) | ||
| Distant metastasis | 21.918 | < 0.01 | ||
| No | 282 (75.2%) | 93 (24.8%) | ||
| Yes | 28 (45.9%) | 33 (54.1%) | ||
| TNM Stages | 95.703 | < 0.01 | ||
| I | 86 (95.6%) | 4 (4.4%) | ||
| II | 95 (91.3%) | 9 (8.7%) | ||
| III | 103 (59.5%) | 70 (40.5%) | ||
| IV | 26 (37.7%) | 43 (62.3%) | ||